Lianhua Pharmaceutical: The unblinding of the main endpoints of Phase III clinical trials of the company's Class 1 new drug LH-1801 tablet combined with metformin met the expected results.

Notice from Lianhuan Pharmaceuticals: The Phase III clinical trial of the company's Class 1 new drug LH-1801 in combination with metformin has completed the unblinding process and recently obtained preliminary data analysis results. This trial uses a multi-center, randomized, double-blind, saxagliptin-controlled method to evaluate the efficacy and safety of LH-1801 in combination with metformin in patients with type 2 diabetes who have inadequate blood sugar control after at least 8 weeks of stable metformin treatment. The study was conducted in 60 centers nationwide, with a total of 615 subjects enrolled. The CRO Run Dong Pharmaceutical R&D Co., Ltd. delivered preliminary statistical analysis results to the company on April 28, 2026, with the main endpoints meeting expectations. We still need to wait for the unblinding and statistical analysis results of the monotherapy project, and only if both studies' final results meet expectations can we submit an application.